Cody Olson, Marlene Maria Girón Bravo, Gisela Gonzalez, Mary Elizabeth Camp
{"title":"Psychopharmacology and Neurocognitive Disorders: Evidence for Cognitive and Behavioral Symptom Management.","authors":"Cody Olson, Marlene Maria Girón Bravo, Gisela Gonzalez, Mary Elizabeth Camp","doi":"10.1176/appi.focus.20250042","DOIUrl":null,"url":null,"abstract":"<p><p>Neurocognitive disorders (NCDs) encompass various conditions that affect cognition and functioning in activities of daily living. Although many types of NCDs lack curative therapy, medications may be used to ameliorate cognitive as well as behavioral and psychological symptoms of dementia (BPSD). Medications classified as acetylcholinesterase inhibitors, <i>N</i>-methyl-D-aspartate receptor antagonists, and antiamyloid monoclonal antibodies target cognitive symptoms. For BPSD, antidepressants, antipsychotics, mood stabilizers, anxiolytics, and stimulants have been studied. Selection of pharmacotherapies requires careful risk-benefit analysis for individual patients. This review discusses available evidence to guide these discussions and clinical decisions.</p>","PeriodicalId":73036,"journal":{"name":"Focus (American Psychiatric Publishing)","volume":"24 2","pages":"179-187"},"PeriodicalIF":0.0000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13337346/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Focus (American Psychiatric Publishing)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1176/appi.focus.20250042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Neurocognitive disorders (NCDs) encompass various conditions that affect cognition and functioning in activities of daily living. Although many types of NCDs lack curative therapy, medications may be used to ameliorate cognitive as well as behavioral and psychological symptoms of dementia (BPSD). Medications classified as acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, and antiamyloid monoclonal antibodies target cognitive symptoms. For BPSD, antidepressants, antipsychotics, mood stabilizers, anxiolytics, and stimulants have been studied. Selection of pharmacotherapies requires careful risk-benefit analysis for individual patients. This review discusses available evidence to guide these discussions and clinical decisions.
神经认知障碍（NCDs）包括影响日常生活活动中的认知和功能的各种疾病。尽管许多类型的非传染性疾病缺乏根治性治疗，但药物可用于改善痴呆（BPSD）的认知、行为和心理症状。归类为乙酰胆碱酯酶抑制剂、n -甲基- d -天冬氨酸受体拮抗剂和抗淀粉样蛋白单克隆抗体的药物靶向认知症状。对于BPSD，已经研究了抗抑郁药、抗精神病药、情绪稳定药、抗焦虑药和兴奋剂。药物治疗的选择需要对个体患者进行仔细的风险-收益分析。这篇综述讨论了现有的证据来指导这些讨论和临床决策。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
